




Name	Jeong-Ok Lee	
Current Position	professor	
Country	South Korea	
Major Field	Lymphoma, BMT, CML	

Educational Background

M.D. 2003	Yeungnam University College of Medicine, Daegu, Korea
M.Sc. 2009	Molecular oncology, Department of Medicine, Graduate School, Seoul National University College of Medicine, Seoul, Korea
Ph.D. 2017	Molecular oncology, Department of Medicine, Graduate School, Seoul National University College of Medicine, Seoul, Korea

Professional Experience

2004-2005	Internship, Seoul National University Hospital, Seoul, Korea
2005-2009	Resident, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
2009-2010	Clinical Fellow, Division of Hemato-oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
2010-2012	Instructor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea
2012-2016	Assistant professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea
2018	Visiting Scholar, Leukemia service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2016-2021	Associate professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea
2021- present	Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea

Other Experience and Professional Memberships

Member of the Korean Society of Hematology
Member of the Korean Society of Blood and Marrow Transplantation
Member of the American Society of Hematology

Main Scientific Publications

Kim DW, Byun JM, Lee JO, Kim JK, Koh Y Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma. JCI insight 2023;8:e164767

Kim SA, Kwon BS, Chung JH, Lee JY, Bang SM, Lee JO. Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review. Ther Adv Respir Dis 2022 Nov 8 doi: [10.1177/17534666221135322](https://doi.org/10.1177/17534666221135322)



Handa S, Lee JO, Derkach A, Stone RM, Saven A, Altman JK, Grever MR, Rai KR, Shukla M, Vemuri S, Montoya S, Taylor J, Abdel-Wahab O, Tallman MS, Park JH. Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy. *Blood* 2022;140:2663-2671

Nawas MT, Lee JO, Flynn J, Maloy M, Jakubowski AA, Papadopoulos EB, Cho C, Ponce DM, Sauter CS, Perales MA, Devlin S, Giralt SA, Castro-Malaspina HR, Tamari R. CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. *Bone Marrow Transplant* 2022;57:1101-1107

Lee JY, Paik JH, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS, Lee JO. R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. *Blood Res* 2021;56:285-292

Byun JM, Shin DY, Koh Y, Hong J, Kim I, Yoon SS, Lee JY, Bang SM, Lee JO. Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission? *Ther Adv Hematol* 2021 Apr 20

Lee JY, Kang M, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Song KH, Kim ES, Kim HB, Lee KW, Kim JH, Bang SM, Lee JS, Lee JO. *Pneumocystis jirovecii* pneumonia in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. *Mycoses* 2021;64:60-65

Byun JM, Lee JO, Suh KJ, Lee J, Shin DY, Koh Y, Hong J, Bang SM, Kim I, Yoon SS. The role of anthracyclines in acute myeloid leukemia consolidation. *Anticancer Res* 2020;40:357-366

Choi M, Lee JO, Jung J, Lee JY, Lee E, Lee H, Bang SM, Eom HS, Lee JS. Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. *Acta Haematol* 2019;141(3):176-186

Lee JO, Lee JY, Chun EJ, Choi SI, Kim JW, Kim SH, Kim YJ, Lee KW, Kim JH, Lee JS, Bang SM. Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. *Support Care Cance*. 2019;27(7): 2507-2515

Byun JM, Kim KH, Kim M, Kim TM, Jeon YK, Park JH, Paik JH, Lee JM, Lee HY, Lee JS, Heo DS, Lee JO. Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. *Leuk Lymphoma*. 2017;58(11): 2624-2632

Suh KJ, Lee JY, Shin DY, Koh Y, Bang SM, Yoon SS, Park S, Kim I, Lee JO. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. *Int J Hematol*. 2017;106(2): 229-239
